Aminopyridine analogs selectively target metastatic pancreatic cancer

Area of Science:

• Oncology
• Metabolic pathways
• Drug discovery

Background:

• Metastatic cancers exhibit unique metabolic adaptations distinct from primary tumors.
• The therapeutic potential of targeting these metastatic-specific metabolic dependencies remains largely unexplored.

Purpose of the Study:

• To identify and target unique metabolic adaptations in pancreatic cancer metastases.
• To evaluate the efficacy and safety of a novel aminopyridine compound, 6-aminopicolamine (6AP), as a potential anti-metastatic therapeutic.

Main Methods:

• Screening of novel aminopyridine compounds for activity against Phosphogluconate Dehydrogenase (PGD).
• In vitro assays to assess the compound's effect on PGD activity, glucose consumption, and histone acetylation.
• In vivo studies in mouse models to evaluate anti-metastatic efficacy and toxicity.

Main Results:

• 6-aminopicolamine (6AP) selectively inhibited Phosphogluconate Dehydrogenase (PGD) in metastatic pancreatic cancer models.
• 6AP reversed key metastatic properties, including tumorigenic capacity, elevated glucose uptake, and global histone hyperacetylation.
• Monotherapy with 6AP demonstrated significant anti-metastatic efficacy with minimal observed toxicity in vivo.

Conclusions:

• 6-aminopicolamine (6AP) is a well-tolerated prodrug with selectivity for metastatic pancreatic cancers.
• Targeting unique metabolic adaptations, such as PGD dependency, represents a promising therapeutic strategy for advanced malignancies.
• Further investigation into 6-aminopyridines may uncover new druggable targets for aggressive cancers.